1 It often infiltrates into neighboring tissues or vessels at an early stage and recurrence after surgical operation is common; therefore, a novel therapeutic strategy is required. Augmentation of a host immune system is an approach to suppress progression of the tumors and their metastasis, and transfer of cytokine genes into pancreatic cancer has been investigated for its clinical feasibility.
P
ancreatic cancer is one of the intractable tumors and the prognosis remained unimproved despite recent progress in therapeutic and detection modalities. 1 It often infiltrates into neighboring tissues or vessels at an early stage and recurrence after surgical operation is common; therefore, a novel therapeutic strategy is required. Augmentation of a host immune system is an approach to suppress progression of the tumors and their metastasis, and transfer of cytokine genes into pancreatic cancer has been investigated for its clinical feasibility. 2, 3 Cytokines released from T helper type 1 (Th1) cells are in particular effective in shifting immune systems into a Th1-dominant state, which enhances cell-mediated immunity. 4 Two novel cytokines, interleukin (IL)-21 and IL-23, were recently identified 5, 6 and their biological properties analyzed in vitro were linked with Th1 functions. IL-21 is secreted primarily from CD4 + T cells and induces proliferation of activated T and natural killer (NK) cells. 5 IL-21 also increases the lytic functions of cytotoxic T and NK cells; 5 thereby, it can enhance antitumor immune responses. The IL-21 receptor complex consists of the common cytokine receptor g chain and IL-21R. 7, 8 A recent study of mice lacking IL-21R demonstrated that IL-21 could facilitate the transition from NK cellmediated innate immunity to T cell-mediated adaptive immunity. 9 However, contradictory results were also reported; IL-21 is secreted from Th2 cells and inhibits the development of interferon-g (IFN-g)-producing Th1 cells. 10 IL-23 is composed of the p19 subunit, which is a novel molecule related to the p35 subunit of IL-12, and the p40 subunit of IL-12. 6 Since IL-23 is structurally related to IL-12, IL-23 can share similar biological activities of IL-12 that facilitates Th1 responses. Both IL-12 and IL-23 are secreted from activated dendritic cells, and enhance proliferation of memory T cells and production of IFNg from activated T cells. 6 However, IL-23 has little effect on naive T cells in contrast to IL-12. IL-23 binds the heterodimeric receptor consisting of IL-12Rb1 and a novel molecule IL-23R, whereas the IL-12 receptor is composed of IL-12Rb1 and IL-12Rb2. 11 These data collectively suggest that IL-21 and IL-23 are possible candidates for immune gene therapy, which enhances cellmediated immunity. We then explored whether these cytokines would produce antitumor effects against human pancreatic cancer in a xenograft model using nude mice and severe combined immunodeficiency (SCID) mice. These mice were also treated with anti-asialo GM 1 antibody to investigate an involvement of NK cells in cytokine-mediated antitumor effects.
Materials and methods

Cells and mice
AsPC-1, C2 (ecotropic) and PA317 (amphotropic packaging cells) cells were obtained from the ATCC (Manassas, VA). AsPC-1 and human lung carcinoma QG-56 cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum, and C2 and PA317 cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal calf serum. Female BALB/c nu/nu and BALB/c scid/scid mice, 6 weeks old, were purchased from Nippon Clea (Tokyo, Japan).
Isolation of murine IL-21 and p19 subunit cDNA
The reverse transcription-based polymerase chain reaction method was used to clone IL-21 and p19 cDNA. RNA was extracted from murine colon carcinoma tumors developed in BALB/c mice and synthesized first-strand cDNAs were amplified with primers; for IL-21, 5 0 -ATTAAAGCTTCTGGTGGCATGGAGAGGAC-3 0 (as a 5 0 primer) and 5 0 -TAGGATCCTGTGTTCTAGGA-GAGATGCTG-3 0 (as a 3 0 primer); for p19, 5 0 -CACA-GAGCCAGCCAGATCTGAGAAGC-3 0 (as a 5 0 primer) and 5 0 -CCATGGGAACCTGGGCATCCTTAAGC-3 0 (as a 3 0 primer). Amplification was performed according to the manufacturer's recommendations (Perkin-Elmer Cetus, Norwalk, CT) and it consisted of 30 cycles under the following conditions: for IL-21, 30 seconds at 941C for denaturation, 30 seconds at 581C for primer annealing and 30 seconds at 721C for primer extension; for p19, 15 seconds at 941C, 30 seconds at 601C and 40 seconds at 721C. The sequence of the product was confirmed to be identical to the published sequences. 5, 6 Transduction of tumor cells was used to harbor IL-21 or p19 plus p40 cDNA. Both the p19 and the p40 genes were linked with an internal ribosomal entry site (IRES) 13 and thereby the transcription of both the p19 (located 5 0 -side to the IRES) and the p40 gene (located 3 0 -side) was activated with the promoter in the long terminal repeats. As a control, LXSN bearing p40 gene alone was also prepared. The retroviral DNA was transfected into ecotropic C2 cells using lipofectin reagent (Invitrogen, Carlsbad, CA) and after the drug selection with G418 (400 mg/ml, Invitrogen), cell-free supernatants of G418-resistant clones were used as a retrovirus stock. The culture supernatants containing the retrovirus were incubated with amphotropic PA317 cells in the presence of 8 mg/ml polybrene (Aldrich, Milwaukee, WI) for infection. Among the G418-resistant PA317 cells, a clone that produced the largest amount of IL-21, p19 or p40 mRNA was selected and the culture supernatants were used for infecting AsPC-1 cells. G418-resistant cells were cloned and used for experiments.
Northern blot analysis
RNA (15 mg) was subjected to electrophoresis on a formaldehyde-agarose gel and transferred to a nylon filter. The filter was hybridized with [a-
32 P]dCTP-labeled murine IL-21, p19, p35 and p40 cDNA in a QuickHib solution (Stratagene, La Jolla, CA) with 0.1 mg/ml salmon sperm DNA at 681C for 1 hour, and then washed with a solution of 0.2 Â SSC/0.1% SDS several times at 651C. The filter was rehybridized with murine elongation factor 1-a (EF1-a) cDNA as a control. 
Animal experiments
Parent or transduced cells (1 Â 10 6 or 5 Â 10 5 ) were injected subcutaneously into nude or SCID mice (n ¼ 7). Anti-asialo GM 1 antibody (50 mg/mouse, Wako, Osaka, Japan) was administered intraperitoneally 1 day before and 4 days after the inoculation of tumor cells. Tumor volumes were calculated according to the formula (1/ 2 Â length Â width 2 ) and statistical analysis was performed by one-way analysis of variance (ANOVA).
Production of IFN-g and detection of the p40 subunit
Spleen cells (1 Â 10 7 /ml) from naive or tumor-bearing nude mice were cultured with 50-Gy-irradiated tumor cells (1 Â 10 6 /ml) in RPMI 1640 medium containing 10% fetal calf serum. Cell-free supernatants collected after 24 hours were examined for the concentrations of IFN-g with an enzyme-linked immunosorbent assay (ELISA, Biosource, Camarillo, CA). The amounts of the p40 subunit in culture supernatants were assayed with an ELISA kit using anti-P40 antibody (Biosource). 
Results
Establishment of IL-21-or IL-23-producing AsPC-1 cells
We retrovirally transduced AsPC-1 cells with the IL-21-or p19-linked p40 genes (AsPC-1/IL-21, AsPC-1/IL-23) and selected two respective G418-resistant clones that expressed either IL-21 (IL-21#1, #9) or p19/p40 mRNA (IL-23#6, #10) at a high level (Fig 1a) . We also examined the amounts of secreted P40 molecules with an ELISA and found that AsPC-1/IL-23#6 and #10 produced 1.1 and 2.0 ng/ml of P40 per 5 Â 10 5 cells for 48 hours, respectively. Since P40 is secreted as monomers and/or homodimers, 14 we established AsPC-1 cells transduced with the p40 gene alone (AsPC-1/p40) as a control, which secreted 1.8 ng/ml P40 per 5 Â 10 5 cells for 48 hours. The expression level of class I molecules of the major histocompatibility complex and that of cell adhesion molecules (CD54 and CD58) on the transduced AsPC-1 cells was comparable to the respective levels on parent cells (Fig 1b, c) , and their proliferation rate in vitro was not different from that of parent cells (data not shown).
Antitumor effects by IL-21 producers
We inoculated parent or transduced AsPC-1 cells into nude mice. Growth of AsPC-1/IL-21#1 tumors was retarded compared with that of parent tumors (after day 11, Po0.05; after day 20, Po0.01, Fig 2a) , whereas the growth of AsPC-1 cells transduced with the retrovirus vector alone was not different from that of parent tumors (data not shown). Growth of AsPC-1/IL-21#9 tumors in nude mice was also similarly retarded as that of AsPC-1/ IL-21#1 tumors (data not shown). We injected anti-asialo GM 1 antibody into nude mice before (day À1) and after tumor inoculation (day 4) in order to examine an involvement of NK cells in the antitumor effects. Injection of the antibody depleted NK cells temporally, but the NK cells reappeared after day 14 (Fig 2c) . Under the experimental condition, the growth of AsPC-1/IL-21#1 tumors in the treated mice was not different from that of parent tumors until day 17, but came to be suppressed thereafter (Fig 2a) . The growth of parent tumors in the antibody-treated mice was not different from that of untreated mice (data not shown).
Growth of AsPC-1/IL-21#1 tumors developed in SCID mice was also retarded compared with that of parent tumors (after day 7, Po0.01, Fig 2b) . Injection of antiasialo GM 1 antibody into SCID mice on days À1 and 4 significantly suppressed the number of NK cells until day 14 (Fig 3c) . The growth of AsPC-1/IL-21#1 tumors in the 
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antibody-treated SCID mice was not different from that of parent tumors until day 15, but then the growth retarded thereafter (Po0.05, Fig 2b) .
Antitumor effects by IL-23 producers
We also examined antitumor effects of IL-23-producing cells in nude and SCID mice. Growth of AsPC-1/IL-23#10 tumors in nude mice was retarded compared with that of parent tumors (after day 20, Po0.05, Fig 3a) , but the level of retardation was not as great as the case of AsPC-1/IL-21#1 tumors. The growth of AsPC-1/p40 tumors, which produced only P40 molecules, was rather enhanced compared with that of parent tumors (after day 29, Po0.05, Fig 3a) . Injection of anti-asialo GM 1 antibody into nude mice did not affect the growth of AsPC-1/IL-23#10 tumors (Fig 3a) . The growth of AsPC-1/IL-23#10 tumors in SCID mice remained the same as that of parent tumors (Fig 3b) .
In vitro analysis
We examined the production of IFN-g from spleen cells of nude mice bearing parent, AsPC-1/IL-21#1 or AsPC-1/ IL-23#10 tumors. When the spleen cells were stimulated with either AsPC-1 or irrelevant QG-56 cells, spleen cells from AsPC-1/IL-21#1 or AsPC-1/IL-23#10 tumor-bearing mice produced IFN-g ( Table 1 ). The amounts of secreted IFN-g responding to AsPC-1 cells were not different from those of IFN-g to QG-56 cells in spleen cells from AsPC-1/IL-21#1 tumor-bearing mice. In AsPC-1/IL-23#10 tumor-bearing mice, production of IFN-g responding to AsPC-1 was relatively greater than that of IFN-g to QG-56 cells; therefore, a certain population of the IFN-g producers in the spleen could recognize tumor specificity. Cytotoxic activities of spleen cells to AsPC-1 or YAC-1 cells were also examined. Spleen cells from the mice bearing AsPC-1/IL-21#1 or AsPC-1/IL-23#10 tumors were cytotoxic to AsPC-1 cells compared with those from naive or parent tumor-bearing mice (Fig 4a) . Enhanced cytotoxicity to YAC-1 cells was observed in spleen cells of AsPC-1/IL-21#1 tumor-bearing mice (Fig 4b) .
Effects by the combination of IL-21 and IL-23 producers and to distant tumors
We examined whether synergistic antitumor activities could be induced by the combinatory inoculation of AsPC-1/IL-21#1 and AsPC-1/IL-23#10 cells (Fig 5a) . Growth of mixed populations of parent and cytokine Cr-labeled target cells. SE bars are also shown.
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producer cells was slower than that of parent tumors, but faster than that of respective cytokine producers. When a mixed population of IL-21 and IL-23 producers was inoculated, the growth retardation of the mixed tumors was not enhanced compared with that of respective tumors.
We also examined whether growth of parent tumors could be retarded by AsPC-1/IL-21#1 or AsPC-1/IL-23#10 cells that were inoculated in the different flank of nude mice (Fig 5b) . The growth of AsPC-1/IL-21#1 or AsPC-1/IL-23#10 tumors was retarded as found in Figs  2a or 3a; however, the growth of parent tumors developed in the opposite flank was not different from that of parent tumors in the nude mice that received parent cells in both flanks.
Discussion
We demonstrated in the present study that the expression of IL-21 and IL-23 in human pancreatic tumors produced antitumor effects in the inoculated immunocompromised mice. IL-21 enhances cytotoxic activity and IFN-g production by activated NK and T cells in vitro, One of the IL-23 subunits, P40 molecules, can be secreted as monomers and/or homodimers (P40 complexes).
14 However, retarded growth of AsPC-1/IL-23#10 tumors was not due to the P40 complexes because growth of AsPC-1/p40 tumors was rather increased compared with that of parent tumors. Since the P40 complexes could be antagonistic to IL-12-mediated immune responses by binding to IL-12 receptors, 14, 16, 17 antitumor responses against AsPC-1 cells in nude mice is currently unknown and a possible antagonistic activity of the P40 complexes to IL-23 needs further investigation. IL-23-mediated antitumor effects observed in the present study was independent of NK cells activity, since treatment of anti-asialo GM 1 antibody did not affect the growth of AsPC-1/IL-23 tumors in nude mice. Loss of IL-23-mediated antitumor effects in SCID mice suggested that gd T and/or NKT cells, both of which were not depleted by anti-asialo GM 1 antibody, 18 could be responsible for the growth retardation of AsPC-1/IL-23 tumors in nude mice. Production of larger amounts of IFN-g in response to AsPC-1, but not to QG-56 cells, also suggested the involvement of gd T cells that can recognize the difference of tumors. 19 Cytotoxic activities detected from AsPC-1/IL-23 tumor-bearing mice could be ascribed to gd T and/or NKT cells. 20 The present data, however, did not exclude the possibility that T cell-mediated responses were generated by IL-23. Immunohistochemical analyses on the cytokine-producing tumors did not reveal migration of any specific types of cells into the tumors.
Although effector cells seemed to be different between the IL-21-and the IL-23-mediated antitumor responses, synergistic antitumor activities by both cytokines were not observed. A recent study showed that IL-21 inhibited IFN-g production from developing Th1 cells and could serve to amplify the Th2 responses. 10 Since the biological outcome of IL-21-induced responses could depend on the cellular context of the IL-21 signals, 10 NK cell-mediated responses induced by IL-21 may be differently modulated by the presence of IL-23. Human pancreatic cancer is susceptible to immunocompetent cells 21 and possible vaccination using gene-modified cancer cells has been clinically examined. 22 However, the cytokine producers used in the present study did not inhibit the growth of parent tumors that were inoculated together or developed in the distant sites. We presume that this incomplete antitumor effects were due to insufficient amounts of cytokines released from the transduced cells and that higher production of local cytokine could evoke stronger immune responses. In conclusion, expression of IL-21 or IL-23 in human pancreatic tumors can induce antitumor effects even in an ab T cell-defective condition and could be a therapeutic strategy for pancreatic cancer patients, who may be suffering from immune tolerance to the tumors.
